

Academic Organizing Partners



# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

A Careful Look Back,  
As You Begin to  
Look Ahead

Fri - 20<sup>th</sup>, Sat - 21<sup>st</sup> & Sun - 22<sup>nd</sup> | Jan-2023

Hotel ITC Grand Central, Mumbai.

Click on the link to register

<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

riveRoute®

Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

Dear Colleagues,

Women's Cancer Initiative - Tata Memorial Hospital and Nag Foundation invite you for the **"8<sup>th</sup> Edition of Year in Review: Breast Cancer Conference"**. This conference will be held in person from **20<sup>th</sup> – 22<sup>nd</sup> Jan 2023 at Hotel ITC Grand Central, Parel, Mumbai.**

The scientific program of the Year in Review stems from data presented at major breast cancer meetings and noteworthy publications from peer reviewed journals, likely to make an impact on our daily clinical practice.

The popularity of the Year in Review Breast Cancer relies on an unbiased selection of high-quality research that is presented in an interactive form and discussed in the Indian context. A wide range of topics are reviewed ranging from Translational Science to Supportive Care.

This aims to give participants clear visibility on how they can apply this information to their immediate practice, as well as keeping in mind the potential of new research.

**The meeting will be broadly classified in the following sessions:**

- Loco-Regional Therapies in Breast Cancer
- ER+ve Breast Cancer
- HER2+ve Breast Cancer
- Triple Negative Breast Cancer
- Translational Science & Supportive Care
- Keynote Presentations and Panel Discussions

YIR has become an important annual meeting in India for breast cancer. We have been going strong since 2016 with your active participation. We request you to circulate this flyer amongst your colleagues and students.

We look forward to your participation to make YIR 2023 successful.

Warm Regards,

## Organising Chairs



**Dr. Sudeep Gupta**  
Director, ACTREC  
Professor of Medical Oncology,  
Tata Memorial Centre, Mumbai



**Dr. Shona Nag**  
Director-Oncology,  
Sahyadri Group of Hospitals,  
Pune

Click on the link to register

<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

**riveroute**

Leaders in Streaming Modules

Academic Organizing Partners



# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

**01**

India's most comprehensive update on breast cancer

**02**

10+ International conferences reviewed

**03**

Five International Speakers

**04**

More than 100 abstracts to be discussed

**05**

Exclusive 45 mins panel discussion

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

## Academic Organizing Partners



## International Faculty



**Dr. Hope Rugo**  
USA



**Dr. Aditya Bardia**  
USA



**Dr. Matteo Lambertini**  
Italy



**Dr. Shaheenah Dawood**  
Dubai



**Dr. Shani Paluch-Shimon**  
Israel

## Conferences Reviewed

### **AACR Annual Meeting**

(American Association for Cancer Research)

### **ASCO Annual Meeting**

(American Society of Clinical Oncology)

### **ESMO Breast Cancer Annual Congress**

(European Society for Medical Oncology)

### **ESMO Annual Congress**

(European Society for Medical Oncology)

### **SABCS Annual Meeting**

(San Antonio Breast Cancer Symposium)

### **ASTRO Annual Meeting**

(American Society for Radiation Oncology)

### **ESTRO Annual Meeting**

(European Society for Radiotherapy & Oncology)

### **Advanced Breast Cancer 6<sup>th</sup> International Consensus Conference**

### **13<sup>th</sup> European Breast Cancer Conference**

### **Milan Breast Cancer Conference**

### **ASBS Annual Conference**

(American Society of Breast Surgeons)

### **Miami Breast Cancer Conference**

### **ABS Annual Meeting**

(Association of Breast Surgery)

### **10<sup>th</sup> Asia-Pacific Breast Cancer Summit**

Click on the link to register

<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

**riveroute**

Leaders in Streaming Modules

## Academic Organizing Partners



### Journals Reviewed

- New England Journal of Medicine
- Journal of Clinical Oncology
- Annals of Oncology
- Annals of Surgery
- Journal of National Cancer Institute
- JAMA Oncology
- The Lancet
- Lancet Oncology
- Nature
- Nature Genetics
- British Journal of Cancer
- European Journal of Cancer
- The Oncologist
- International Journal of Radiation Oncology, Biology & Physics
- Clinical Cancer Research
- Journal of Experimental & Clinical Cancer Research
- JAMA Cardiology
- PLOS Genetics
- Breast Cancer Research
- Bio Medical Central

*~ And many more*

### Websites Reviewed

- Practice Update
- ASCOPOST
- ASCO Reading Room
- Clinical Cancer Options
- Prime Oncology
- Medscape
- Oncolive

*~ And many more*

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

8<sup>th</sup> YEAR IN REVIEW  
**BREAST  
CANCER**

The year that was...2022

“

## Highlights of the Meeting

- » Selected publications shortlisted from 30+ journals
- » Selected abstracts from major cancer conferences
- » State of the art keynote talks
- » Meet National experts
- » Extended rapid review session

”

“

## Session Classification

- » Loco-Regional therapies in breast cancer
- » ER+ve Breast Cancer
- » HER2+ve Breast Cancer
- » Triple Negative Breast Cancer
- » Translational Science & Supportive Care
- » Keynote Presentations and Panel Discussions

”

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**<sup>®</sup>  
Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## International Speaker



### **Dr. Hope Rugo, USA**

Clinical Professor, Department of Medicine (Hematology/Oncology); and Director, Breast Oncology Clinical Trials Program, UCSF San Francisco, CA

Dr. Hope Rugo is a medical oncologist and hematologist specializing in breast cancer research and treatment. A Clinical Professor of Medicine, Dr. Rugo joined the Breast Care Center in 1999 after a decade of experience at UCSF in malignant hematology and bone marrow transplantation for a variety of diseases, including breast cancer. She entered the field of breast cancer in order to incorporate novel therapies based on an understanding of the biology of cancer with excellent quality of care into the treatment of women with breast cancer.

Dr. Rugo is the Director of the Breast Oncology Clinical Trials Program, and is the principal investigator of multiple clinical trials focusing on combining novel targeted therapeutics with standard treatment to improve the treatment of both early and late stage breast cancer. In addition, Dr. Rugo is working on studies to evaluate cognitive function in women receiving chemotherapy for breast cancer, as well as novel ways to reduce toxicity from therapy. Dr. Rugo has established collaborations with a number of other large academic medical centers for the purpose of expanding the novel therapies that are available for our patients, including herbal agents that appear to have an antitumor effect in the laboratory. She is an active member of the national cooperative group, CALGB, and is a founding member of the Breast Cancer Research Consortium, as well as serving as an investigator in the UCSF Breast SPORE (the Bay Area Specialized Program of Research Excellence in Breast Cancer).

Click on the link to register

<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

**riveroute**

Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## International Speaker

Dr. Rugo teaches medical students and physicians, and regularly lectures locally, nationally and internationally on subjects relating to the treatment of breast cancer. At UCSF, Dr. Rugo runs the Breast Forum, an open bimonthly evening educational session for breast cancer patients, families and friends from throughout the bay area.

Dr. Rugo graduated from the University of Pennsylvania School of Medicine in 1983. She completed a residency in internal medicine and primary care followed by a fellowship in hematology and oncology at the University of California San Francisco. She was a post-doctoral fellow in immunology participating in laboratory research at Stanford University from 1988-1990.

In 1990, Dr. Rugo joined the faculty at UCSF in the Division of Hematology and Oncology. Dr. Rugo has been recognized for her excellence in both patient care and in teaching of both medical students and training physicians. She has received several awards including the Bank of America Gianini Foundation Award and a UCSF Clinical Cancer Center Investigator Research Program intramural award. In 2006, she was honored for her work in Breast Cancer Research by the Friends of the Breast Care Center.

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

**riveroute**<sup>®</sup>

Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## International Speaker



### **Dr. Aditya Bardia**

Assistant Professor, Medicine, Harvard Medical School  
Attending Physician, Medical Oncology,  
Massachusetts General Hospital,  
Boston, USA

Dr. Bardia is interested in developing successful targeted and personalized therapies to improve the outcomes of patients and families afflicted with breast cancer. The accurate identification of target is crucial for success of targeted therapies, and Dr. Bardia is involved in the clinical development of tumor genotyping as well as circulating tumor cells (CTCs) to facilitate accurate diagnosis, therapy selection, and real-time monitoring of breast cancer. In collaboration the CTC center and Haber lab, his research on molecular changes in CTCs in metastatic breast cancer has elucidated the role of epithelial-mesenchymal transition, and provided proof-of-principle that ex-vivo CTC culture and molecular drug testing is feasible in breast cancer. Dr. Bardia is the principal investigator of clinical trials investigating the role of targeted therapy combinations, including novel ER agents and CDK 4/6 inhibitors, for patients with breast cancer. Dr. Bardia is the recipient of Young Investigator Award from the ASCO Conquer Cancer Foundation and Career Catalyst Award for Susan K Komen Foundation. Dr. Bardia is on the editorial board of ASCO University and faculty member of molecular tumor board by ASCO University.

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## International Speaker



### **Dr. Matteo Lambertini**

Adjunct Professor and Consultant,  
Medical Oncology,  
University of Genova in Genova, Italy

Dr. Matteo Lambertini is mainly focused in the care of breast cancer patients and is deeply involved in cancer research. He has a particular expertise in the management of breast cancer in young women, with a specific attention to the fertility and pregnancy-related issues that they have to face after diagnosis.

With the support of ESMO, in 2018 he completed his PhD at the Universite Libre de Bruxelles (U.L.B.) in Brussels (Belgium) with a project entitled “Unmet Fertility and Pregnancy - related Issues in Young Breast Cancer Patients”.

He is member of the guideline group on fertility preservation in cancer patients for the European Society for Medical Oncology (ESMO), the European Society of Human Reproduction and Embryology (ESHRE) and the Italian Association of Medical Oncology (AIOM).

He has authored more than 170 publications in peer-reviewed journals and book chapters in the field of breast cancer in young women. His most important research conducted so far addressed the role of administering gonadotropin-releasing hormone (GnRH) analogs during chemotherapy as a strategy to preserve ovarian function and fertility in early breast cancer patients who are candidates to receive cytotoxic therapy, the safety of having a pregnancy in women with prior history of breast cancer, and the impact of carrying a germline BRCA mutation on patients' fertility and pregnancy-related issues.

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

**riveroute**<sup>®</sup>

Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## International Speaker



### **Dr. Shaheenah Dawood**

President, UAE Cancer Congress

Co-President, Asia Pacific Breast Cancer Summit (ABCS)

Head, Consultant Medical Oncologist,  
Mediclinic Parkview Hospital, Dubai

Dr. Dawood is an extremely experienced oncologist. She graduated from Dubai Medical College in 1998 and undertook further training within Dubai Health Authority before attaining a Medical Oncology fellowship from McGill University, Montreal, Canada and the Susan Komen Breast Cancer fellowship from the University of Texas M.D. Anderson Cancer Center, Houston, USA.

She attained her Master of Public Health from the Harvard School of Public Health in 2008 and has over 100 papers to her credit including 34 peer review original articles, 15 review articles and 9 book chapters. She is also an Editorial Fellow of the New England Journal of Medicine and serves as a reviewer for multiple journals including the Journal of Clinical Oncology. She currently serves as President of the UAE Cancer Congress that is held annually in Dubai and is Co-President of the Asia-Pacific Breast Cancer Summit (APBCS).

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

**riveroute**<sup>®</sup>

Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## International Speaker



### **Dr. Shani Paluch-Shimon**

Director, Breast Oncology Program,  
Sharett Oncology Institute,  
Hadassah University Hospital,  
Jerusalem, Israel

Dr. Shani Paluch-Shimon is the Director of Breast Oncology at Hadassah University Hospital in Jerusalem, which includes a dedicated service for the care and treatment of young women with breast cancer. She has a Master's degree in epidemiology from the London School of Hygiene & Tropical Medicine and leads both clinical and epidemiological research. She is a graduate of the Talpiot physician leadership program (Sheba).

She is the subject editor for breast cancer treatment guidelines for the European Society for Medical Oncology, key faculty in several international oncology societies & multi-stakeholder organizations and a member of the Israeli National Cancer Council. Her key areas of clinical interest and research are breast cancer in young women, BRCA-associated breast cancer, triple-negative breast cancer and neo-adjuvant therapies. She has co-authored over 60 scientific papers and has authored ESO-ESMO\* international guidelines on breast cancer in young women, the ESMO clinical practice guidelines on screening and prevention of cancer in individuals with a hereditary breast and ovarian cancer syndrome. She is a member of the ESO-ESMO international consensus panel for the management of advanced breast cancer and a member of the European consensus panel on genetic testing in advanced breast cancer.

Dr. Paluch-Shimon is currently a member of the ESMO Breast Faculty, a core faculty member in the European School of Oncology and co-chair of the European School of Oncology's Breast Cancer in Young Women Conference. She was a member of the Israeli Ministry of Health committee evaluating the national breast cancer screening policy.

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

**rive**route®

↳ Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

FRIDAY, 20<sup>TH</sup> JANUARY, 2023

### Pre-Conference Industrial Symposiums

18:45 – 19:30	● Industrial Symposium 1
19:30 – 20:30	● Industrial Symposium 2
20:30 – 21:00	● Industrial Symposium 3
21:00 Onwards	Networking & Dinner

FRIDAY, 20<sup>TH</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

### Pre-Conference Workshop Quality Oncology Practice Initiative

08:00 – 08:05	• Welcome and Introduction
08:05 – 08:45	• ASCO Quality Programs Overview <ul style="list-style-type: none"><li>• Quality Oncology Practice Initiative (QOPI) Program</li><li>• QOPI Certification Program</li><li>• Quality Training Program</li></ul>
08:45 – 08:55	• Q&A Discussion

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

### Session 1 : Loco-Regional Breast Cancer

- |               |   |
|---------------|---|
| 08:55 – 09:00 | ● Welcome and Introduction  |
| 09:00 – 09:10 | ● Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108)<br><i>Citation: J ClinOncol. 2022 Mar 20;40(9):978-987.<br/>Author: Seema A Khan</i>  |
|               | ● Multi-Institutional Validation of a Mammography-Based Breast Cancer Risk Model<br><i>Citation: J ClinOncol. 2022 Jun 1;40(16):1732-1740.<br/>Author: Adam Yala</i>  |
|               | ● Effect of peri-tumoral infiltration of local anaesthetic prior to surgery on survival in early breast cancer<br><i>Citation: ESMO Congress 137MO<br/>Annals of Oncology (2022) 33 (suppl_7): S55-S84.<br/>Author: R.A. Badwe</i>  |
| 09.10 – 09.20 | ● Intelligent Vacuum-Assisted Biopsy to Identify Breast Cancer Patients With Pathologic Complete Response (ypT0 and ypN0) After Neoadjuvant Systemic Treatment for Omission of Breast and Axillary Surgery<br><i>Citation: J ClinOncol. 2022 Jun 10;40(17):1903-1915<br/>Author: André Pfob</i> |
|               | ● Surrogacy of Pathologic Complete Response in Trials of Neoadjuvant Therapy for Early Breast Cancer: Critical Analysis of Strengths, Weaknesses, and Misinterpretation<br><i>Citation: JAMA Oncol. 2022 Nov 1;8(11):1668-1675.<br/>Author: Fabio Conforti</i>                                  |
|               | ● Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: A multicentre, single-arm, phase 2 trial<br><i>Citation: Lancet Oncol. 2022 Dec;23(12):1517-1524.<br/>Author: Henry M Kuerer</i>   |

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

8<sup>th</sup> YEAR IN REVIEW  
**BREAST  
CANCER**  
The year that was...2022



**SCIENTIFIC PROGRAM**



**DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023**

**Session 1 : Loco-Regional Breast Cancer**

09:20 – 09:30	<ul style="list-style-type: none"><li>● Identifying Patients Whose Symptoms Are Underrecognized During Treatment With Breast Radiotherapy <i>Citation: JAMA Oncol. 2022 Jun 1;8(6):887-894. Author: Reshma Jagsi</i></li><li>● Effect of Supine vs Prone Breast Radiotherapy on Acute Toxic Effects of the Skin Among Women With Large Breast Size: A Randomized Clinical Trial <i>Citation: JAMA Oncol. 2022 Jul 1;8(7):994-1000. Author: Danny Vesprini</i></li><li>● Hypofractionated Radiotherapy in patients with Breast Cancer (HRBC): Acute toxicity data of a phase III randomized study <i>Citation: SABCS GS5-12 Author: Budhi Singh Yadav</i></li></ul>
09:30 – 09:37	<ul style="list-style-type: none"><li>● Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial: The Danish Breast Cancer Group Partial Breast Irradiation Trial <i>Citation: J ClinOncol. 2022 Dec 20;40(36):4189-4197. Author: Birgitte V Offersen</i></li><li>● Effect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer: A Randomized Phase 3 Clinical Trial <i>Citation: JAMA Oncol. 2022 Jan 1;8(1):96-105. Author: Yong Bae Kim</i></li></ul>
09:38 – 09:45	<ul style="list-style-type: none"><li>● Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial <i>Citation: J ClinOncol. 2022 Nov 16;JCO2201565. Author: Sanne A L Bartels</i></li></ul>

**DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023**



Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

### Session 1 : Loco-Regional Breast Cancer

	<ul style="list-style-type: none"><li>NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). ASCO 1007 <i>Citation: Journal of Clinical Oncology 40, no. 16_suppl (June 01, 2022) 1007-1007.</i> <i>Author: Steven J. Chmura</i></li></ul>
09:46 – 09:52	<ul style="list-style-type: none"><li>GS4-02 Oncological outcomes following omission of axillary lymph node dissection in node positive patients downstaging to node negative with neoadjuvant chemotherapy: The OPBC-04/EUBREAST-06/OMA study <i>Citation: SABCS GS4-02</i> <i>Author: Montagna G</i></li><li>Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: A multicentre pooled analysis of 5161 patients <i>Citation: Lancet Oncol. 2022 Jan;23(1):149-160.</i> <i>Author: Christina Yau</i></li></ul>
09:53 – 10:00	<ul style="list-style-type: none"><li>Primary radiotherapy and deep inferior epigastric perforator flap reconstruction for patients with breast cancer (PRADA): A multicentre, prospective, non-randomised, feasibility study <i>Citation: Lancet Oncol. 2022 May;23(5):682-690.</i> <i>Author: Paul T R Thiruchelvam</i></li><li>GS4-05 Phase II randomized trial of conventional versus hypofractionated post-mastectomy proton radiotherapy <i>Citation: SABCS GS4-05</i> <i>Author: Mutter R.</i></li></ul>

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

### Session 1 : Loco-Regional Breast Cancer

10:00 – 10:07

- GS4-03 Validation of Profile for the Omission of Local Adjuvant Radiotherapy (POLAR) in a meta-analysis of three randomized controlled trials of breast conserving surgery +/- radiotherapy

*Citation: SABCS GS4-03*

*Author: Karlsson P.*

- LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC).

*Citation: ASCO LBA501*

*Journal of Clinical Oncology 40, no. 17\_suppl (June 10, 2022) LBA501-LBA501.*

*Author: Timothy Joseph Whelan*

10:08 – 10:25

- **Locoregional (Rapid Review)**
- Mortality After Late Breast Cancer Recurrence in Denmark  
*Citation: J Clin Oncol. 2022 May 1;40(13):1450-1463*  
*Author: Rikke Nørgaard Pedersen*
- Ductal Carcinoma In Situ and Breast Cancer Over diagnosis  
*Citation: Journal of Clinical Oncology 40, no. 14 (May 10, 2022) 1595-1595.*  
*Author: Ismail Jatoi*
- Tools for Contralateral Prophylactic Mastectomy Decision Making  
*Citation: J Clin Oncol. 2022 Nov 1;40(31):3653-3659.*  
*Author: Mitchell H Gail*
- Digital breast tomosynthesis plus synthesised mammography versus digital screening mammography for the detection of invasive breast cancer (TOSYMA): A multicentre, open-label, randomised, controlled, superiority trial  
*Citation: Lancet Oncol. 2022 May;23(5):601-611.*  
*Author: Walter Heindel*

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

Click on the link to register

<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

riveroute®

Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

### Session 1 : Loco-Regional Breast Cancer

- De-escalation of radiotherapy after primary chemotherapy in cT1-2N1 breast cancer (RAPCHEM; BOOG 2010-03): 5-year follow-up results of a Dutch, prospective, registry study  
*Citation: Lancet Oncol. 2022 Sep;23(9):1201-1210*  
*Author: Sabine R de Wild*
- Treatment-related thoracic soft tissue sarcomas in US breast cancer survivors: A retrospective cohort study  
*Citation: Lancet Oncol. 2022 Nov;23(11):1451-1464.*  
*Author: Lene H S Veiga*
- Incidence of Anaplastic Large-Cell Lymphoma of the Breast in the US, 2000 to 2018  
*Citation: JAMA Oncol. 2022 Sep 1;8(9):1354-1356.*  
*Author: Connor J Kinslow*
- FLASH Radiotherapy for the Treatment of Symptomatic Bone Metastases (FAST-01): Protocol for the First Prospective Feasibility Study  
*Citation: JMIR Res Protoc. 2022 Oct 4.*  
*Author: Emily C Daugherty*
- Contributions of screening, early-stage treatment, and metastatic treatment to breast cancer mortality reduction by molecular subtype in U.S. women, 2000-2017.  
*Citation: ASCO 2022 Abstract 1008*  
*Journal of Clinical Oncology 40, no. 16\_suppl (June 01, 2022) 1008-1008.*  
*Author: Jennifer Lee Caswell-Jin*
- GS4-01 Impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer  
*Citation: SABCS GS4-01*  
*Author: Boughey JC*

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

### Session 1 : Loco-Regional Breast Cancer

10:25 – 11:10

- Panel Discussion on Key abstracts in Loco-regional cancers

11:10 – 11:30

Tea/Coffee Break

11:30 – 11:38

- Adjuvant Pertuzumab And Trastuzumab In Patients With Early HER-2 Positive Breast Cancer In Aphinity: 8.4 Years' Follow-Up  
*Citation: ESMO VIRTUAL PLENARY ABSTRACT| VOLUME 33, ISSUE 9, P986-987, SEPTEMBER 01, 2022*  
*Author: S. Loibl*
- De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): Survival outcomes from a multicentre, open-label, randomised, phase 2 trial  
*Citation: Clinical Trial Lancet Oncol. 2022 May;23(5):625-635.*  
*Author: Ulrike Nitz*

11:38 – 11:47

- Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): Final overall survival analysis Randomized Controlled Trial  
*Citation: Ann Oncol. 2022 Mar;33(3):321-329.*  
*Author: G Curigliano*
- Clinical Profile and Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer With Brain Metastases: Real-World Experience  
*Citation: JCO Glob Oncol. 2022 Sep;8:e2200126.*  
*Author: Prabhat Bhargava*

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

### Session 2 : HER2+ve Breast Cancer

- Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial

*Citation: ESMO Breast Cancer Congress 165MO*  
*Author: Rupert Bartsch*

11:48 – 12:00

- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

*Citation: Clinical Trial N Engl J Med. 2022 Mar 24;386(12):1143-1154.*  
*Author: Javier Cortés*

- Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC)

*Citation: ESMO Breast Cancer Congress 163O*  
*Author: Giuseppe Curigliano*

- Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.

*Citation: ASCO 2022 Abstract 1000*  
*Author: Erika P. Hamilton*

- GS2-02: Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated survival results of the randomized, phase 3 study DESTINY-Breast03

*Citation: SABCS/GS2-02*  
*Author: Sara Hurvitz*

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

Click on the link to register

<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

riveroute®

Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

### Session 2 : HER2+ve Breast Cancer

12:00 – 12:08

- Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals  
*Citation: Cancers (Basel). 2022 May; 14(9): 2114.*  
*Author: Clelia Chalumeau*
- Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial  
*Citation: ESMO Congress LBA18*  
*Author: Fabrice André*

12:09 – 12:20

- **HER2+ve Breast Cancer Rapid Review**
- Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study  
*Citation: J ClinOncol. 2022 Feb 10;40(5):438-448..*  
*Author: Ian E Krop*
- Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial  
*Citation: J ClinOncol. 2022 Sep 1; 40(25): 2946-2956.*  
*Author: Huober*

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

### Session 2 : HER2+ve Breast Cancer

- Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer: The Neo-PATH Phase 2 Nonrandomized Clinical Trial

*Citation: JAMA Oncol. 2022 Sep 1;8(9):1271-1277.  
Author: Hee Kyung Ahn*

- Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): A multicentre, single-arm, two-cohort, phase 2 trial

*Citation: Clinical Trial Lancet Oncol. 2022 Mar;23(3):353-361. doi: 10.1016/S1470-2045(21)00716-6. Epub 2022 Jan 31.  
Author: Min Yan*

- Cost-effectiveness Analysis of Pertuzumab With Trastuzumab in Patients With Metastatic Breast Cancer

*Citation: JAMA Oncol. 2022 Apr 1;8(4):597-606.  
doi: 10.1001/jamaoncol.2021.8049.  
Author: Wei Fang Dai*

- Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial

*Citation: ESMO Congress LBA19  
Annals of Oncology (2022) 33 (suppl\_7):  
S808-S869.10.1016/annonc/annonc1089  
Author: Binghe Xu*

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

### Session 2 : HER2+ve Breast Cancer

- Dose-expansion study of trastuzumab deruxtecan as monotherapy or combined with pertuzumab in patients with metastatic human epidermal growth factor receptor 2-positive (HER2+) breast cancer in DESTINY-Breast07 (DB-07).

*Citation: SABCS Abstract PD18-11*  
*Author: Hamilton EP*

12:20 – 12:45

- HER2 low breast cancer : A New entity ?

12:45 – 13:30

- Panel discussion on key abstracts of HER2+ve Breast Cancer

13:30 – 14:15

Lunch Break

### Session 3 : Triple Negative Breast Cancer

14:15 – 14:30

- Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

*Citation: Ann Oncol. 2022 May;33(5):534-543.*  
*Author: L Gianni*

- Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

*Citation: Ann Oncol. 2022 Nov;33(11):1149-1158.*  
*Author: S Loibl*

- Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.

*Citation: ASCO 2022 Abstract 503*  
*Author: Lajos Pusztai*

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

### Session 3 : Triple Negative Breast Cancer

- HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522

*Citation: ESMO Congress 135MO*

*Author: R.A. Dent*

- Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer(KN 552)

*Citation: N Engl J Med 2022; 386:556-567*

*Author: Peter Schmid*

14:30 – 14:45

- CALGB 40603 (Alliance): Long-Term Outcomes and Genomic Correlates of Response and Survival After Neoadjuvant Chemotherapy With or Without Carboplatin and Bevacizumab in Triple-Negative Breast Cancer

*Citation: J ClinOncol. 2022 Apr 20;40(12):1323-1334.*

*Author: Jonathan H Shepherd*

- Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrightNess, a randomized phase III trial

*Citation: Ann Oncol. 2022 Apr;33(4):384-394.*

*Author: C E Geyer*

- Moment of truth-adding carboplatin to neoadjuvant/adjuvant chemotherapy in triple negative breast cancer improves overall survival: An individual participant data and trial-level Meta-analysis

*Citation: Breast. 2022 Aug;64:7-18.*

*Author: Neha Pathak*

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

Click on the link to register

<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

riveRoute®

Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

### Session 3 : Triple Negative Breast Cancer

	<ul style="list-style-type: none"><li>• Addition of platinum to sequential taxane-anthracycline neoadjuvant chemotherapy in patients with triple-negative breast cancer: A phase III randomized controlled trial <i>Citation: SABCS : GS5-01</i> <i>Author: Gupta S.</i></li></ul>
14:45 – 15:00	<ul style="list-style-type: none"><li>• Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): End-of-study results from a randomised, phase 3 trial <i>Citation: Lancet Oncol. 2022 Dec;23(12):1571-1582.</i> <i>Author: Lucia Del Mastro</i></li><li>• Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM) <i>Citation: ESMO Congress 1340</i> <i>Author: Lucia Del Mastro</i></li><li>• Pre-specified event driven analysis of overall survival (OS) in the Olympia Phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (GBRCAM) associated breast cancer <i>Citation: Ann Oncol. 2022;May; 33(5): 566-568</i> <i>Author: A.N.J. Tutt</i></li></ul>
15:00 – 15:10pm	<ul style="list-style-type: none"><li>• Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer <i>Citation: N Engl J Med. 2022 Jul 21;387(3):217-226.</i> <i>Author: Javier Cortes</i></li></ul>

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

### Session 3 : Triple Negative Breast Cancer

- Health-Related Quality of Life (HRQoL) With Pembrolizumab (pembro) + Chemotherapy -(chemo) vs Placebo (pbo) + Chemo as 1L Treatment for Advanced Triple-Negative Breast Cancer (TNBC): Results From KEYNOTE-355

*Citation: ESMO Breast Cancer Congress 1640*

*Author: D.W. Cescon*

- Oncologists' Perspectives on Individualizing Dose Selection for Patients With Metastatic Cancer

*Citation: JCO OncolPract. 2022*

*Nov;18(11):e1807-e1817.*

*Author: Rachel B Jimenez*

15:10 – 15:25

- **TNBC Rapid Review**

- Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial

*Citation: Journal of Clinical Oncology 40, no. 10 (April 01, 2022) 1051-1058.*

*Author: Heikki Joensuu*

- Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial

*Citation: JAMA Oncol. 2022 Jul 1;8(7):1010-1018.*

*Author: Jens-Uwe Blohmer*

- Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial

*Citation: JAMA Oncol. 2022 Dec 1;8(12):1802-1808.*

*Author: Pierre Loap*

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

Click on the link to register

<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

riveRoute®

↳ Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

### Session 3 : Triple Negative Breast Cancer

- Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: Results of exploratory analyses from the phase III BROCADE3 trial

*Citation: Ann Oncol. 2022 Mar;33(3):299-309.  
Author: H S Han*

- Treatment With Etirinotecan Pegol for Patients With Metastatic Breast Cancer and Brain Metastases: Final Results From the Phase 3 ATTAIN Randomized Clinical Trial

*Citation: JAMA Oncol. 2022 Jul 1;8(7):1047-1052.  
Author: Debu Tripathy*

- Primary endpoint analysis of a randomized phase II of darolutamide or capecitabine in patients with triple-negative androgen receptor-positive advanced breast cancer (UCBG3-06 START trial)

*Citation: ESMO Congress 213MO  
Author: M. Arnedos*

15:25 – 15:55

- State-of-the-science : Hereditary breast cancer

15:55 – 16:40

- Panel discussion on key abstracts of TNBC

16:40 – 16:55

Tea/Coffee Break

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

Click on the link to register

<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

rive<sup>route</sup>

Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

### Session 4 : Translational (Rapid Review)

16:55 – 17:10

- Circulating tumor DNA (ctDNA) and serum thymidine kinase 1 activity (TKa) matched dynamics in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated in first-line (1L) with ribociclib (RIB) and letrozole (LET) in the BioltaLEE trial.  
*Citation: ASCO 2022 Abstract 1012*  
*Author: Grazia Arpino*
- Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer  
*Citation: J ClinOncol.*  
*2022 Aug 1;40(22):2408-2419.*  
*Author: Marla Lipsyc-Sharf*
- Use of real-world data (RWD) to assess the utility of cell-free circulating tumor DNA (cfDNA) in identifying resistance to early treatment in advanced breast cancer (aBC).  
*Citation: ASCO 2022 Abstract 1011*  
*Author: Seth Andrew Wander*
- GS3-09 Circulating Tumor Cells-driven choice of first line therapy for ER+ HER2- metastatic breast cancer: Overall survival analysis of the randomized STIC CTC trial  
*Citation: SABCS GS3-09*  
*Author: Bidard F-C*
- Evaluating the Role of Circulating MicroRNAs to Aid Therapeutic Decision Making for Neoadjuvant Chemotherapy in Breast Cancer: A Prospective, Multicenter Clinical Trial  
*Citation: Ann Surg. 2022 Nov 1;276(5):905-912.*  
*Author: Matthew G Davey*

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

### Session 4 : Translational (Rapid Review)

17:10 – 17:25

- Optimal 18F-FDG PET/CT (FDG-PET) cut-off for pathological complete response (pCR) prediction in HER2-positive [HER2+] early breast cancer (EBC) patients (pts) treated with neoadjuvant trastuzumab (T) and pertuzumab (P) in PHERGain trial

*Citation: ESMO Breast Cancer Congress 91MO*  
*Author: Géraldine Gebhart*

- Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

*Citation: EBioMedicine. 2022 Jan;75:103801.*  
*Author: Aleix Prat*

- Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial.

*Citation: ASCO 2022 Abstract 510*  
*Author: Alexandra Thomas*

- HER2DX genomic test in HER2-positive / hormone receptor-positive (HER2+/HR+) breast cancer (BC) treated with neoadjuvant trastuzumab (T) and pertuzumab (P): A correlative analysis from the PerELISA trial

*Citation: ESMO Breast Cancer Congress 140MO*  
*Author: Valentina Guarneri*

- Unraveling the mechanism of action and resistance to Trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial

*Citation: ESMO Breast Cancer Congress LBA1*  
*Author: Maria Fernanda Mosele*

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

### Session 4 : Translational (Rapid Review)

- Development of a prognostic gene-expression signature for early stage HER2-positive breast cancer patients

*Citation: ESMO Breast Cancer Congress: 2MO*  
*Author: Serena Di Cosimo*

- Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial

*Citation: ESMO Breast Cancer Congress 139MO*  
*Author: Mattia Rediti*

- Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials.

*Citation: ASCO 2022 Abstract 509*  
*Author: Aranzazu Fernandez-Martinez*

17:25 – 17:40

- Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy

*Citation: Journal of Clinical Oncology 40, no. 21 (July 20, 2022) 2361-2374.*

*Author: Vincent M.T. de Jong*

- GS5-05 ZNF689 deficiency promotes intratumor heterogeneity and resistance to immune checkpoint blockade in triple-negative breast cancer

*Citation: SABCS GS5-05*

*Author: Ge L-P*

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

riveRoute®

Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

### Session 4 : Translational (Rapid Review)

- The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2.

*Citation: ASCO 2022 Abstract 514*

*Author: Lorenza Mittempergher*

- GS5-07 Estradiol represses anti-tumoral immune response to promote progression of triple-negative breast cancer brain metastases

*Citation: SABCS GS5-07*

*Author: Contreras-Zarate MJ*

- Results from plasmaMATCH trial cohort E: A phase II trial of olaparib and ceralasertib in patients with triple-negative advanced breast cancer (CRUK/15/010).

*Citation: Journal of Clinical Oncology 40, no. 16\_suppl (June 01, 2022) 1024-1024.*

*Author: Alistair E. Ring*

- Association of the research-based HER2DX signatures with survival in early-stage triple-negative breast cancer (eTNBC)

*Citation: ESMO Breast Cancer congress 3 MO*

*Author: Benedetta Conte*

17:40 – 17:50

- Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC)

*Citation: ESMO Congress 2100*

*Author: Antonio Marra*

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

Click on the link to register

<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

riveroute®

Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

### Session 4 : Translational (Rapid Review)

- GS3-07 Clonal evolution and mechanisms of acquired resistance to CDK4/6 inhibitors in ER-wild type and ER-mutant breast cancer  
*Citation: SABCS GS3-07*  
*Author: Guarducci C*
  - Allelic dosage of RB1 drives CDK4/6 inhibitor treatment resistance in metastatic breast cancer.  
*Citation: ASCO 2022 Abstract 1010*  
*Author: Anton Mikhailovich Safonov*
  - ESR1 F404 mutations and acquired resistance to fulvestrant in the plasmaMATCH study.  
*Citation: ASCO 2022 Abstract 1009*  
*Author: Belinda Kingston*
- 17:50 – 18:00
- GS5-08 Soluble E-cadherin: A novel prognostic biomarker and driver of brain metastasis in inflammatory breast cancer  
*Citation: SABCS GS5-08*  
*Author: Hu X*
  - GS4-06 Radiomic phenotypes of breast texture and association with breast cancer risk and masking  
*Citation: SABCS GS4-06*  
*Author: Winham S*
  - Breast Cancers Are Immunogenic: Immunologic Analyses and a Phase II Pilot Clinical Trial Using Mutation-Reactive Autologous Lymphocytes  
*Citation: J Clin Oncol. 2022 Jun 1;40(16):1741-1754*  
*Author: Nikolaos Zacharakis*

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

### Session 4 : Translational (Rapid Review)

- GS5-06 InteractPrint predicts clinically meaningful interactions between cancer epithelial cells and immune cells: Lessons from a single-cell breast cancer atlas

*Citation: SABCS GS5-06*

*Author: Xu L*

- Development of an automated liquid biopsy assay for methylated markers in advanced breast cancer

*Citation: Cancer Res Commun. 2022*

*Jun;2(6):391-401*

*Author: Mary Jo Fackler*

### Session 5 : Molecular Tumor Board : Case Discussion

18:00 – 18:40

- Molecular Tumor Board : Case Discussion

DAY 1, SATURDAY, 21<sup>ST</sup> JANUARY, 2023

Click on the link to register

<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

riveroute®

Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

### Session 6 : Supportive Care

09:00 – 09:10

- Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis  
*Citation: Journal of Clinical Oncology 40, no. 19 (July 01, 2022) 2148-2162.*  
*Author: Ines Vaz-Luis*
- Dynamics of Long-Term Patient-Reported Quality of Life and Health Behaviors After Adjuvant Breast Cancer Chemotherapy  
*Citation: Journal of Clinical Oncology 40, no. 27 (September 20, 2022) 3190-3204.*  
*Author: Antonio Di Meglio*
- Patient-reported cognitive impairment in women participating in the RxPONDER trial (SWOG S1007) by menopausal status  
*Citation: SABCS GSI-04*  
*Author: Kang*

09:10 – 09:20

- Long-term Quality of Life in Patients With Breast Cancer After Breast Conservation vs Mastectomy and Reconstruction  
*Citation: JAMA Surg. 2022;157(6):e220631*  
*Author: Summer E. Hanson*
- Association of Breast-Conserving Therapy with Measures of Long-term Quality of Life Compared With Mastectomy and Reconstruction  
*Citation: JAMA Surg. 2022;157(6):e220637*  
*Author: Sudheer Vemuru*
- Prophylactic Use of Compression Sleeves Reduces the Incidence of Arm Swelling in Women at High Risk of Breast Cancer-Related Lymphedema: A Randomized Controlled Trial  
*Citation: J Clin Oncol. 2022 Jun 20;40(18):2004-2012*  
*Author: Vincent S Paramanandam*

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

Click on the link to register

<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

riveroute<sup>®</sup>

Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

### Session 6 : Supportive Care

	<ul style="list-style-type: none"><li>Prospective Surveillance for Breast Cancer-Related Arm Lymphedema: A Systematic Review and Meta-Analysis <i>Citation: Journal of Clinical Oncology 40, no. 9 (March 20, 2022) 1009-1026</i> <i>Author: Bolette S. Rafn</i></li></ul>
09:20 – 09:30	<ul style="list-style-type: none"><li>Chemotherapy-induced peripheral neuropathy (CIPN) prevention trial evaluating the efficacy of hand-cooling and compression in patients undergoing taxan-based (neo-)adjuvant chemotherapy for primary breast cancer: First results of the prospective, randomized POLAR trial <i>Citation: ESMO Congress 15520</i> <i>Author: Laura Michel</i></li><li>The Effects of vaginal testosterone versus placebo on female sexual function: Interim analysis of the PIVoT (Prevention of Recurrent Urinary Tract Infection using Vaginal Testosterone) Trial <i>Citation: SMSNA 2022; Abstract 2</i> <i>Author: Martinez, M</i></li><li>Characterization of alpelisib-associated hyperglycemia in metastatic breast cancer <i>Citation: ASCO 2022 Abstract 1016</i> <i>Author: Sherry Shen</i></li><li>Omega-3 in The Treatment of Mood and Sleep Disorders Induced by Hormone Therapy in Women with Breast Cancer: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial <i>Citation: <a href="https://doi.org/10.21203/rs.3.rs-1055943/v1">https://doi.org/10.21203/rs.3.rs-1055943/v1</a></i> <i>Author: Behzad Nouroosi</i></li></ul>

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

### Session 6 : Supportive Care

09:30 – 09:40

- The role of Yoga as a complementary therapy in women undergoing treatment for breast cancer: A randomized controlled trial

*Citation: SABCS Abstract PD8-04*

*Author: Nair N.S*

- Mapping Systematic Reviews of Breast Cancer Survivorship Interventions: A Network Analysis

*Citation: J Clin Oncol. 2022 Jul 1;40(19):2083-2093*

*Author: Emma B Kemp*

- Moving the Translational Needle in Breast Cancer Survivorship: Connecting Intervention Research to Clinical Practice

*Citation: J Clin Oncol. 2022 Jul 1;40(19):2069-2073*

*Author: Eden R Brauer*

09:40 – 10:10

- Fertility issues in young breast cancer patients: What women want

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

Click on the link to register

<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

riveroute®

Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

### Session 7 : ER+ve Breast Cancer

10:10 – 10:20

- Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)  
*Citation: J Clin Oncol. 2022 Jan 20;40(3):282-293*  
*Author: Michael Gnant*
- Adjuvant Abemaciclib Combined with Endocrine Therapy (ET): Efficacy Results in monarchE Cohort 1  
*Citation: ESMO Breast Cancer Congress 59MO*  
*Author: Mattea Reinisch*
- Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy A Prespecified Analysis of the monarchE Randomized Clinical Trial  
*Citation: JAMA Oncol. 2022;8(8):1190-1194*  
*Author: Miguel Martin*
- Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: Results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes  
*Citation: SABCS: GS1-09*  
*Author: Johnston S*

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

### Session 7 : ER+ve Breast Cancer

10:20 - 10:30

- Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial  
*Citation: J Clin Oncol. 2022 Apr 20;40(12):1335-1345*  
*Author: Josephine M N Lopes Cardozo*
- Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer  
*Citation: J Clin Oncol. 2022 Aug 10;40(23):2557-2567*  
*Author: Ulrike A Nitz*
- GS5-10 Utility of the 70-gene MammaPrint test for prediction of extended endocrine therapy benefit in patients with early-stage breast cancer in the IDEAL Trial  
*Citation: SABCS//GS5-10*  
*Author: Liefers G-J*

10:30 - 10:42

- Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: A patient-level meta-analysis of 7030 women from four randomised trials  
*Citation: Lancet Oncol. 2022 Mar;23(3):382-392*  
*Author: Early Breast Cancer Trialists' Collaborative Group (EBCTCG)*
- Extended adjuvant aromatase inhibition after sequential endocrine therapy: Final results of the phase III DATA trial  
*Citation: ESMO Congress 1330*  
*Author: V.C.G. Tjan-Heijnen*

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

### Session 7 : ER+ve Breast Cancer

- Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial

*Citation: J Clin Oncol. 2022 Dec 10;40(35):4071-4082*

*Author: Annelie Johansson*

- Adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: 8-year follow-up of the randomized ASTRRA trial

*Citation: ASCO 2022 Abstract 506*

*Author: Soo Yeon Baek*

10:43 - 10:52

- Long-term outcomes of adjuvant denosumab in breast cancer: Fracture reduction and survival results from 3,425 patients in the randomised, double-blind, placebo-controlled ABCSG-18 trial

*Citation: ASCO 2022 Abstract 507*

*Author: Michael Gnant*

- Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+ HER2- breast cancer and a high genomic grade index: The Unicancer ASTER 70s trial

*Citation: ASCO 2022 Abstract 500*

*Author: Etienne Brain*

- Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial

*Citation: GSI-06*

*Author: O'Regan R*

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

Click on the link to register

<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

riveroute®

Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

### Session 7 : ER+ve Breast Cancer

10:53 - 11:02

- Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ER+/HER2- ABC): Analyses from PALOMA-2  
*Citation: ASCO 2022 LBA1003*  
*Author: Richard S. Finn*
- Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2- advanced breast cancer (ABC) MONARCH 3  
*Citation: ESMO Breast Cancer Congress LBA15*  
*Author: Matthew Goetz*
- Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer  
*Citation: N Engl J Med 2022; 386:942-950*  
*Author: Hortobagyi Gabriel N*

11:03 - 11:14

- Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2- advanced breast cancer treated with ribociclib + endocrine therapy vs physician's choice combination chemotherapy  
*Citation: SABCS: GS1-10*  
*Author: Lu Y-S*
- Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): A randomised, open-label, multicentre, phase 3 trial.  
*Citation: The Lancet. Oncology, 29 Sep 2022, 23(11):1367-1377*  
*Author: Bidard FC*

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

### Session 7 : ER+ve Breast Cancer

- Association between ER, PR and HER2 levels and outcome under palbociclib (Pal) + aromatase inhibitors (AIs) as first-line therapy for ER+ HER2- metastatic breast cancer (MBC): An exploratory analysis of the PADA-1 trial  
*Citation: ESMO Breast Cancer Congress 167 MO*  
*Author: Thibault de La Motte Rouge*
- Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer  
*Citation: Cancer. 2022 Sep 1;128(17):3224-3232.*  
*Author: Nathan W. Watson*

11:15 - 11:25

- Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor-positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis  
*Citation: ASCO 2022 Abstract 1005*  
*Author: Robert Hugh Jones*
- A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial  
*Citation: ASCO 2022 LBA1003*  
*Author: Kevin Kalinsky*

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

### Session 7 : ER+ve Breast Cancer

- Clinical Validity of 16 $\alpha$ -[18F]Fluoro-17 $\beta$ -Estradiol Positron Emission Tomography/Computed Tomography to Assess Estrogen Receptor Status in Newly Diagnosed Metastatic Breast Cancer

*Citation: J Clin Oncol. 2022 Nov 1;40(31):3642-3652*

*Author: Jasper J L van Geel*

11:25 - 11:40

### Tea/Coffee Break

11:40 - 11:52

- **ER+ve Early Breast Cancer (Rapid Review)**
- Daily Oral Ibandronate With Adjuvant Endocrine Therapy in Postmenopausal Women with Estrogen Receptor-Positive Breast Cancer (BOOG 2006-04): Randomized Phase III TEAM-IIB Trial

*Citation: Journal of Clinical Oncology 40, no. 25 (September 01, 2022) 2934-2945*

*Author: Sonja B. Vliek*

- Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, HER2-ve Primary Breast Cancer

*Citation: J Clin Oncol. 2022 Nov 10;40(32):3699-3708*

*Author: Thomas Bachelot*

- Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: Safety and patient-reported outcomes from the monarchE study

*Citation: Ann Oncol. 2022 Jun;33(6):616-627*

*Author: H S Rugo*

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

rive<sup>route</sup>

Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

### Session 7 : ER+ve Breast Cancer

- Historical early treatment effects of adjuvant endocrine therapy for breast cancer in high-risk subgroups: Reanalysis of BIG 1-98, SOFT and TEXT

*Citation: ASCO 2022 Abstract 508*

*Author: Meredith M. Regan*

- A randomized presurgical trial of alternative dosing of exemestane in postmenopausal women with early-stage ER-positive breast cancer

*Citation: ASCO 2022 Abstract 519*

*Author: Andrea De Censi*

- A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial

*Citation: ASCO 360922*

*Journal of Clinical Oncology 40, no. 36\_suppl (October 20, 2022) 360922-360922*

*Author: Wendy Y. Chen*

- Risk of Endometrial Polyps, Hyperplasia, Carcinoma, and Uterine Cancer After Tamoxifen Treatment in Premenopausal Women with Breast Cancer

*Citation: JAMA Netw Open. 2022;5(11):e2243951*

*Author: Ki-Jin Ryu*

- Trial Assigning Individualized Options for Treatment (TAILORx): An update including 12-year event rates

*Citation: SABCS: GS1-05*

*Author: Sparano J*

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

Click on the link to register

<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

rive<sup>route</sup>

Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

### Session 7 : ER+ve Breast Cancer

11:53 - 12:02

- **ER+ve MBC (Rapid Review)**
  - Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): Overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial  
*Citation: Lancet Oncol. 2022 Jul;23(7):851-864*  
*Author: Sacha J Howell*
  - Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer  
*Citation: JNCI: Journal of the National Cancer Institute, Volume 114, Issue 11, November 2022, Pages 1511-1522*  
*Author: Steffi Oesterreich*
  - Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC).  
*Citation: ASCO 2022 Abstract 1015*  
*Author: Hope S. Rugo*
  - Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+/HER2- advanced breast cancer (ABC) in MONALEESA(ML)-2  
*Citation: ASCO 2022 Poster 1017*  
*Author: Hart*

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

# 8<sup>th</sup> YEAR IN REVIEW BREAST CANCER

The year that was...2022

## SCIENTIFIC PROGRAM

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

### Session 7 : ER+ve Breast Cancer

	<ul style="list-style-type: none"> <li>● Palbociclib After CDK4/6i and Endocrine Therapy (PACE): A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for Endocrine Pre-treated ER+/HER2- Metastatic Breast Cancer</li> </ul> <p><i>Citation: SABCS : GS3-06</i> <i>Author: Mayer EL</i></p>
12:03 - 13:00	<ul style="list-style-type: none"> <li>● Panel discussion on key abstracts of ER+ve Breast Cancer</li> </ul>
13:00 - 13:30	<ul style="list-style-type: none"> <li>● New and upcoming treatments in breast cancer: 5 to 10 years horizon</li> </ul>
13:30 - 13:45	<ul style="list-style-type: none"> <li>● Did you know?</li> </ul>
13:45 - 13:50	<ul style="list-style-type: none"> <li>● Vote of thanks</li> </ul>
13:50 - 14:45	Lunch

### Post Conference Industrial Symposiums

14:45 - 15:30	<ul style="list-style-type: none"> <li>● Industrial Symposium 4</li> </ul>
15:30 - 16:15	<ul style="list-style-type: none"> <li>● Industrial Symposium 5</li> </ul>

DAY 2 - SUNDAY, 22<sup>ND</sup> JANUARY, 2023

Click on the link to register  
<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner  
**riveroute**  
Leaders in Streaming Modules

8<sup>th</sup> YEAR IN REVIEW  
**BREAST  
CANCER**

The year that was...2022

## Registration Fees

**20<sup>th</sup> Jan to 22<sup>nd</sup> Jan 2023**

<b>Delegates</b>	<b>Rs. 1,500</b>
<b>Students</b>	<b>Rs. 500</b>

## Conference Secretariat

**Ms. Rezwina D'souza**

Mobile No: +91 98194 63663

E-mail: rrcg.rezwina@gmail.com

River Route Creative Group, Mumbai

Click on the link to register

<https://in.eregnow.com/ticketing/register/yir2023>

Scientific Event Partner

**riveroute**

Leaders in Streaming Modules